Marqibo

DRUG2 trials

Sponsors

Acrotech Biopharma Inc., Therapeutic Advances in Childhood Leukemia Consortium

Conditions

ALL, ChildhoodBrain TumorsLeukemiaLymphoblastic Leukemia, AcuteLymphoblastic Leukemia, Acute, ChildhoodLymphomaNeuroblastomaSarcoma

Phase 1

To Evaluate the Safety, Activity and Pharmacokinetics of Marqibo in Children and Adolescents With Refractory Cancer

CompletedNCT01222780

Acrotech Biopharma Inc.Brain Tumors, Leukemia, Lymphoma +3

Start: 2010-09-30End: 2014-12-31Updated: 2020-01-18

Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy

CompletedNCT02879643

Therapeutic Advances in Childhood Leukemia ConsortiumALL, Childhood, Lymphoblastic Leukemia, Acute, Lymphoblastic Leukemia, Acute, Childhood

Start: 2017-01-31End: 2024-12-31Updated: 2025-10-22

Related Papers

Vincristine Sulfate Liposome Injection With Combination Chemotherapy for Children, Adolescents, and Young Adults With Relapsed Acute Lymphoblastic Leukemia: A Therapeutic Advances in Childhood Leukemia and Lymphoma Consortium Trial

Pediatric Blood & Cancer2025-02-12

Immunotherapies for Pediatric B-Cell Acute Lymphoblastic Leukemia Patients

Oncology Times2019-04-25